|
Volumn 66, Issue 7, 2002, Pages 1279-1280
|
Obesity
|
Author keywords
[No Author keywords available]
|
Indexed keywords
ACARBOSE;
AMFEPRAMONE;
BETA 3 ADRENERGIC RECEPTOR STIMULATING AGENT;
CAFFEINE;
CHOLECYSTOKININ RECEPTOR STIMULATING AGENT;
DEXFENFLURAMINE;
EPHEDRINE;
FENFLURAMINE;
FLUOXETINE;
GLUCOCORTICOID;
GROWTH HORMONE;
LEPTIN;
MAZINDOL;
NEUROPEPTIDE Y RECEPTOR ANTAGONIST;
PHENTERMINE;
PHENYLPROPANOLAMINE;
SIBUTRAMINE;
SUCROSE POLYESTER;
TETRAHYDROLIPSTATIN;
ARTICLE;
BODY MASS;
CANCER;
CARDIOVASCULAR DISEASE;
CLINICAL TRIAL;
CUSHING SYNDROME;
DIABETES MELLITUS;
DRUG EFFECT;
DYSLIPIDEMIA;
ENVIRONMENTAL FACTOR;
GENETIC RISK;
HUMAN;
HYPERTENSION;
INCIDENCE;
MATHEMATICAL ANALYSIS;
MORTALITY;
NEUROENDOCRINE DISEASE;
OBESITY;
OSTEOARTHRITIS;
OVARY POLYCYSTIC DISEASE;
PREVALENCE;
PROGNOSIS;
RISK FACTOR;
SLEEP APNEA SYNDROME;
STROKE;
UNITED STATES;
WEIGHT GAIN;
WEIGHT REDUCTION;
ADULT;
ANTI-OBESITY AGENTS;
EVIDENCE-BASED MEDICINE;
HUMANS;
LACTONES;
OBESITY;
PROGNOSIS;
RISK FACTORS;
|
EID: 0036791821
PISSN: 0002838X
EISSN: None
Source Type: Journal
DOI: None Document Type: Article |
Times cited : (3)
|
References (6)
|